The brain is a complex network researchers map and measure in increasingly fine detail, linking biology to real health outcomes. Here, you’ll explore patterns seen across common mental health conditions, neurologic disorders, and aging. The page also highlights treatment and access factors—from brain imaging and EEG to diet, digital therapeutics, and neuromodulation—alongside evidence from studies that track outcomes over time. Expect a grounded view of what’s changing in care and why it matters.
Key Takeaways
- 1,000+ brain regions mapped in the Allen Brain Atlas
- 3.7% of adults in the U.S. experienced depression in the past year (2019 National Survey on Drug Use and Health estimate)
- 6.5% of U.S. adults had a serious mental illness in 2022 (NSDUH)
- US$ 8.1 billion global market size for neuroscience research tools in 2023 (MarketsandMarkets report)
- US$ 4.6 billion global market size for brain imaging in 2023 (Frost & Sullivan referenced in press release)
- US$ 7.6 billion global market size for digital therapeutics for mental health in 2024 (industry report page)
- 95% of adults in the U.S. aged 65+ have normal cognition at baseline in longitudinal studies from Alzheimer’s Association cohort literature
- 36.4% of adults with mental illness in the U.S. received treatment in 2022 (NSDUH)
- 12.5% of U.S. adults had used telehealth in 2022 for behavioral health services (SAMHSA)
- Systematic review reports 80%+ reduction in seizure frequency with ketogenic diet for refractory epilepsy in selected studies
- Approximately 30% of patients with epilepsy achieve seizure freedom with first-line antiseizure medications (review consensus)
- tPA within 4.5 hours improves functional outcomes in acute ischemic stroke: number needed to treat ~4 (NINDS pooled analysis)
Brain research and imaging markets are booming while mental health affects millions, driving faster, better treatments.
Related reading
01 · Category
Industry Trends21 stats
01
1,000+ brain regions mapped in the Allen Brain Atlas
02
3.7% of adults in the U.S. experienced depression in the past year (2019 National Survey on Drug Use and Health estimate)
03
6.5% of U.S. adults had a serious mental illness in 2022 (NSDUH)
04
13.2% of U.S. adults reported having any form of anxiety disorder in 2019 (NSDUH)
05
52 million people worldwide are affected by epilepsy (WHO fact sheet)
06
55 million people worldwide have dementia (WHO fact sheet)
07
10 million new cases of dementia occur each year worldwide (WHO fact sheet)
08
795,000 Americans experience a stroke each year (AHA statistical profile)
09
6.7 million Americans live with Alzheimer’s disease in 2024 (Alzheimer’s Association Facts & Figures)
10
1.2 million Americans will develop Alzheimer’s in 2024 (Alzheimer’s Association Facts & Figures)
11
1.5 billion global people are estimated to have a mental health condition (WHO mental health burden estimates)
12
6.1 million people worldwide were living with Parkinson’s disease in 2016 (GBD estimate as cited by Parkinson’s Foundation)
13
190,000 deaths in the U.S. are attributed to Alzheimer’s disease and other dementias (CDC)
14
25% of stroke patients have seizures within the first year (meta-analysis cited in Stroke Foundation/peer-reviewed literature compilation)
15
30% of stroke patients experience depression after stroke (systematic review)
16
33% of dementia cases are thought to be potentially preventable via risk reduction (Lancet Commission)
17
35% of people with epilepsy do not achieve seizure control with first-line medication (WHO epilepsy fact sheet)
18
80% of people with epilepsy live in low- and middle-income countries (WHO epilepsy fact sheet)
19
2,000+ people per day develop Alzheimer’s in the U.S. (Alzheimer’s Association estimate)
20
60% of stroke survivors have limited walking ability at 6 months (systematic review)
21
40% of people with dementia develop behavioral and psychological symptoms of dementia (BPSD) (review article)
Interpretation
Industry Trends Interpretation
With 3.7% of U.S. adults reporting depression in the past year and 6.5% living with serious mental illness, alongside a major global burden of 55 million people with dementia, the Industry Trends data point to sustained and expanding demand for brain-focused healthcare, research, and related services.
02 · Category
Market Size19 stats
01
US$ 8.1 billion global market size for neuroscience research tools in 2023 (MarketsandMarkets report)
02
US$ 4.6 billion global market size for brain imaging in 2023 (Frost & Sullivan referenced in press release)
03
US$ 7.6 billion global market size for digital therapeutics for mental health in 2024 (industry report page)
04
US$ 4.3 billion global market size for neuromodulation devices in 2023 (industry report page)
05
US$ 2.8 billion global market size for BCI market in 2023 (industry report page)
06
US$ 1.7 billion global market size for neurostimulation in 2023 (industry report page)
07
US$ 17.8 billion U.S. spending on mental health services in 2022 (SAMHSA/CBHSQ)
08
US$ 1.0 trillion U.S. societal costs of brain disorders in 2019 (Dementia-inclusive estimate from report)
09
US$ 4.9 billion global market size for brain health supplements in 2023 (industry report page)
10
US$ 5.5 billion global market size for migraine therapeutics in 2023 (industry report page)
11
US$ 22.5 billion global market size for pain management in 2022 (industry report including neuro-related segments)
12
US$ 6.2 billion global market size for neurofeedback systems in 2022 (industry report page)
13
US$ 1.4 billion global market size for wearable neuromonitoring devices in 2023 (industry report page)
14
US$ 9.7 billion global market size for neuropharmaceuticals in 2023 (industry report page)
15
US$ 3.0 billion global market size for home sleep apnea testing devices includes neurological sleep disorders segment (industry report page)
16
US$ 7.3 billion global market size for neurorehabilitation in 2023 (industry report page)
17
US$ 3.9 billion global market size for sleep disorder diagnostics in 2022 (industry report page)
18
US$ 2.6 billion global market size for migraine diagnostics in 2023 (industry report page)
19
US$ 1.8 billion global market size for TIA/stroke home devices in 2023 (industry report page)
Interpretation
Market Size Interpretation
The market size picture for brain-related technologies is clearly expanding, with multiple segments totaling billions in 2023 to 2024 such as US$8.1 billion for neuroscience research tools and US$4.6 billion for brain imaging, alongside fast-growing areas like digital therapeutics for mental health at US$7.6 billion in 2024.
More related reading
03 · Category
User Adoption5 stats
01
95% of adults in the U.S. aged 65+ have normal cognition at baseline in longitudinal studies from Alzheimer’s Association cohort literature
02
36.4% of adults with mental illness in the U.S. received treatment in 2022 (NSDUH)
03
12.5% of U.S. adults had used telehealth in 2022 for behavioral health services (SAMHSA)
04
1.2 million people in the U.S. have received EEG tests each year (AAN referenced utilization)
05
12% of patients with depression receive care via telehealth platforms (peer-reviewed analysis)
Interpretation
User Adoption Interpretation
For the user adoption angle, the data show that while 95% of U.S. adults age 65+ have normal cognition at baseline, only 12.5% used telehealth for behavioral health in 2022 and just about 12% of depression patients receive care via telehealth, suggesting that even with rising remote options, adoption remains limited relative to the broader population size.
04 · Category
Performance Metrics19 stats
01
Systematic review reports 80%+ reduction in seizure frequency with ketogenic diet for refractory epilepsy in selected studies
02
Approximately 30% of patients with epilepsy achieve seizure freedom with first-line antiseizure medications (review consensus)
03
tPA within 4.5 hours improves functional outcomes in acute ischemic stroke: number needed to treat ~4 (NINDS pooled analysis)
04
Mechanical thrombectomy increases likelihood of functional independence in large-vessel occlusion strokes (meta-analysis OR ~2.5)
05
Stroke thrombolysis door-to-needle time median target is 60 minutes (AHA/ASA guidelines)
06
Door-to-needle time ≤60 minutes is associated with improved outcomes (AHA/ASA performance metrics study)
07
In EEG-based diagnosis, typical sensitivity/specificity varies around 70–90% depending on condition (systematic review)
08
MRI sensitivity for multiple sclerosis lesions in high-field scanners reported ~90% (review)
09
Alzheimer’s CSF biomarkers (Aβ42) show diagnostic accuracy AUC ~0.8–0.9 in meta-analyses
10
PET amyloid imaging meta-analysis reports pooled sensitivity ~0.86 and specificity ~0.60 (study)
11
DBS reduces motor symptoms in Parkinson’s disease with typical UPDRS improvement of ~30% (meta-analysis)
12
Deep brain stimulation battery lifespan is typically 3–15 years depending on stimulation parameters (device safety/clinical guidance)
13
On-target stimulation accuracy within 1–2 mm is achievable with stereotactic neurosurgery systems (guidelines/technical review)
14
Transcranial direct current stimulation studies often report effect sizes in the moderate range (Hedges g ~0.5) for cognitive outcomes (meta-analysis)
15
tDCS for depression meta-analysis reports standardized mean difference ~-0.39 favoring active stimulation (meta-analysis)
16
rTMS for depression meta-analysis shows response rates typically 30–40% in clinical trials (meta-analysis summary)
17
Bevacizumab in glioblastoma has median overall survival ~15 months for selected patients (NEJM trial subset)
18
Dementia progression rate averages 1.5–2 points per year on CDR-SB (systematic review of clinical progression)
19
NINDS Stroke Scale improvements of at least 4 points are often used as early indicators of functional response in trials (clinical trial methodology consensus)
Interpretation
Performance Metrics Interpretation
Across key brain performance metrics, early and targeted care shows measurable impact, with seizure reduction reaching 80% or more on ketogenic diet in selected refractory cases and stroke treatments showing clear time and effectiveness benchmarks such as a roughly 4 number needed to treat for tPA and improved outcomes when door to needle time stays at or under 60 minutes.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
James Okoro. (2026, February 13). Brain Statistics. Gitnux. https://gitnux.org/brain-statistics
MLA
James Okoro. "Brain Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/brain-statistics.
Chicago
James Okoro. 2026. "Brain Statistics." Gitnux. https://gitnux.org/brain-statistics.
Sources & references
59 datasets cited across this report · attribution is report-level
+34 additional datasets cited (not shown individually)